Acadia Pharma (ACAD) on Watch Amid Unconfirmed Takeover Chatter Involving Biogen (BIIB)
- Wall Street gains, helped by oil, economic data
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- Unusual 11 Mid-Day Movers 12/5: (NVCN) (BCEI) (MEMP) Higher; (GTXI) (CERC) (HDSN) Lower
- Oil hits 16-month high in buying rush after OPEC agreement
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sanofi (SNY) Said to Explore Counterbid for Actelion Amid Johnson & Johnson (JNJ) Talks - Bloomberg
- Acadia Pharma (ACAD) Commences Pimavanserin Phase 2 in MDD
- LPL Financial (LPLA) Weakens as CEO Retirement Said to Hint That Sale is Off